Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell LymphomaFrancine M. Foss, Madeleine Duvic, David C. Fisher et al.|Journal of Clinical Oncology|2024Cited by 22
Efficacy and Safety of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302Francine M. Foss, Madeleine Duvic, Youn H. Kim et al.|Blood|2022Cited by 15
Safety and Tolerability of E7777 (improved purity Denileukin diftitox [ONTAK]) in Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma: Results from Pivotal Study 302H. Miles Prince, Francine M. Foss, Larisa J. Geskin et al.|Blood|2022Cited by 4